Tumor necrosis factor genetic polymorphisms correlate with infections after liver transplantation

Transplantation

Volumn 67, Issue 7, 1999, Pages 1005-1010

  Freeman Jr , Richard B ^a,b   Tran, Cam Ly ^a   Mattoli, Jessica ^a   Patel, Ketaky ^a   Supran, Stacey ^a   Basile, Frank G ^a   Krishnamurthy, Savitri ^a   Aihara, Rie ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECIPIENT; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY; SURVIVAL;

ADULT; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; INFECTION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POSTOPERATIVE COMPLICATIONS; SURVIVAL ANALYSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0345643436     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199904150-00012     Document Type: Article

References (48)

1. Beutler B, Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med 1987; 316: 379.
2. Jordan SC, Czer L, Toyoda M, et al. Serum cytokine levels in heart allograft recipients: correlation with findings on endomyocardial biopsy. J Heart Lung Transplant 1993; 12: 333.
3. Chollet-Martin S, Depoix JP, Hvass U, et al. Raised plasma levels of tumor necrosis factor in heart allograft rejection. Transplantation Proc 1990; 22: 283.
4. Rolfe MW Kunkle S, Lincoln P, et al. Lung allograft rejection: role of tumor necrosis factor-alpha and interleukin-6. Chest 1993; 103: 133S.
5. McGlaughlin PJ, Aikawa A, Davies HM, et al. Evaluation of sequential plasma and urinary tumor necrosis factor alpha levels in renal allograft recipients. Transplantation 1991; 51: 1225.
6. Dorge SE, Roux-Lombard P, Dayer JM, et al. Plasma levels of tumor necrosis factor and soluble TNF receptors in kidney transplant recipients. Transplantation 1994; 58: 1000.
7. Blancho G, Moreau JF, Ghabannes D, et al. HILDA/LDF, G.CSF, IL-1 beta, IL-6, and TNF alpha production during acute rejection of human kidney allografts. Transplantation Proc 1993; 25: 891.
8. Noguchi K, Yoshida Y, Yagihashi A, et al. Serum levels of interleukin-6, tumor necrosis factor-alpha, and interleukin-2 in rejection of human small bowel allografts. Transplantation Proc 1992; 24: 1152.
9. Gerwal H, Kotb M, Salem A, et al. Elevated tumor necrosis factor levels are predictive for pancreas allograft transplant rejection. Transplantation Proc 1993; 25: 132.
10. Imagawa DK, Millis JM, Olthoff KM, et al. The role of tumor necrosis factor in allograft rejection. Transplantation 1990; 50: 219.
11. Hoffman MW, Wonigei K, Steinhoff G, et al. Production of cytokines (TNF-alpha, IL-1 beta) and endothelial cell activation in human liver allograft rejection. Transplantation 1993; 55: 329.
12. Hamilton G, Prettenhofer M, Zommer A, et al. Intraoperative course and prognostic significance of endotoxin, tumor necrosis factor-alpha and interleukin-6 in liver transplant recipients. Immunobiology 1991; 182: 425.
13. Noronha IL, Hartley B, Cameron JS, Waldherr R. Detection of IL-1 beta and TNF-alpha message and protein in renal allograft biopsies. Transplantation 1993; 56: 1026.
14. Morel D, Normand E, Lemoine C, et al. Tumor necrosis factor alpha in human kidney transplant rejection - analysis by in situ hybridization. Transplantation 1993; 55: 773.
15. Arbustini E, Grasso M, Diegoli M, et al. Expression of tumor necrosis factor in human cardiac rejection. An immunohistochemical and immunoblotting study. Am J Pathol 1991; 139: 709.
16. Krams SM, Falco DA, Villanueva JC et al. Cytokine and T-cell receptor gene expression at the site of allograft rejection. Transplantation. 1992; 53: 151.
17. Heidenreich S, Lang D, Tepel M, Rahn KH. Monocyte activation for enhanced tumor necrosis factor-alpha and interleukin-6 production during chronic renal allograft rejection. Transplant Immunol 1994; 2: 35.
18. Hancock WH, Whitely WD, Tullius SG, et al. Cytokines, adhesion molecules, and the pathogenesis of chronic rejection of rat renal allografts. Transplantation 1993; 56: 643.
19. Seu P, Imagawa DK, Wasef E, et al. Monoclonal anti-tumor necrosis factor-alpha antibody treatment of rat cardiac allografts: synergism with low dose cyclosporine and immunohistochemical studies. J Surg Res 1991; 50: 520.
20. Lin H, Chensue SW, Strieter RM, et al. Antibodies against tumor necrosis factor prolong cardiac allograft survival in the rat. J Heart Lung Transplant 1192; 11: 330.
21. Coito AJ, Binder J, Brown LF, et al. Anti-TNF-alpha treatment down-regulates the expression of fibronectin and decreases cellular infiltration of cardiac allografts in rats. J Immunol 1995; 1995; 2949.
22. Eason JD, Wee S, Kawai T, et al. Inhibition of the effects of TNF in renal allograft recipients using recombinant human dimeric tumor necrosis factor receptors. Transplantation 1995; 59: 300.
23. Clausell N, Molossi S, Sett S, Rabinovitch M. In vivo blockade of tumor necrosis factor-alpha in cholesterol-fed rabbits after cardiac transplant inhibits acute coronary artery neointimal formation. Circulation 1994; 89: 2768.
24. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS. Role of transcriptional activation of IκB in mediation of immunosuppression by glucocorticoids. Science 1995; 270: 283.
25. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M, Immunosuppression by glucocorticoids: Inhibition of NFκB activity through induction of IκB synthesis. Science 1995; 270: 286.
26. Members of the American College of Chest Physicians/Society of Critical Care Consensus Conference Committee: American College of Chest Physicians/Society of Critical Care Consensus Conference: definitions for sepsis and organ failure and guidelines for use of innovative therapy in sepsis. Crit Care Med 1992; 20: 864.
27. Waage A, Brandtzaeg P, Halstensen A, et al. The complex pattern of cytokines in serum from patients with meningococcal septic shock. J Exp Med 1989; 169: 333.
28. Debets JM, Kampmeijer R, van-der-Linden, et al. Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med 1989; 17: 489.
29. Marino MW, Dunn A, Grail D, et al. Characterization of TNF deficient mice. Proc Nat Acad Sci 1997; 94: 8093.
30. Abraham E, Wunderlink R, Silverman R, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. JAMA 1995; 273: 934.
31. Fisher CJJ, Agosti JM, Opal SM, et al. Treatment of septic shock with tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 1996; 334: 1697.
32. Nedwin GE, Naylor SL, Sakaguchi AY, et al. Human lymphotoxin and tumor necrosis factor genes: Structure, homology and chromosomal location. Nucleic Acids Res 1985; 13: 6361.
33. Piciot F, Molvig J, Wogensen L, et al. A tumor necrosis factor beta polymorphism in relation to monokine secretion and insulin-dependent diabetes mellitus. Scand J Immunol 1991; 33: 37.
34. Piciot F, Briant L, Jongeel CV, et al. Association of tumor necrosis factor (TNF) and class II major histocompatability complex alleles with the secretion of TNF-alpha and TNF-beta by human mononuclear cells: A possible link to insulin-dependent diabetes. Eur J Immonol 1993; 23: 224.
35. Messer G, Spengler U, Jung MC, et al. Polymorphic structure of the tumor necrosis factor (TNF) locus: An NcoI polymorphism in the first intron. J Exp Med 1991; 173: 209.
36. Webb GC, Chaplin DD. Genetic variability at the human tumor necrosis factor loci. J Immunol 1990; 145: 1278.
37. Stuber F, Petersen M, Bokelmann F, Schade U. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-α concentrations and outcome of patient with severe sepsis. Crit Care Med 1996; 24: 381.
38. Jackson W, Konieczny B, Bray B, et al. Graft outcome following clinical kidney transplantation correlates with polymorphisms of the TNFB locus. American Society of Transplant Physicians Meeting 1993 (abstract).
39. Goeken NE, Greazel NA, Johnson MM, and Hunsicker LG. TNFB genetics and renal allograft rejection. A lesson in unexpected results and confounding variables. American Society of Transplant Physicians Meeting 1994 (abstract).
40. Mahoney RJ, Szatkowski MA, White B, Leeber DA. Tumor necrosis factor β gene polymorphism and early primary kidney allograft loss. Hum Immunol 1996; 50: 148.
41. Fugger L, Morling N, Ryder LP, et al. NcoI restriction fragment length polymorphism (RFLP) of the tumor necrosis factor (TNFα) region in four autoimmune diseases. Tissue Antigen 1989; 34: 17.
42. Fugger L, Morling L, Ryder LP, et al. NcoI restriction fragment length polymorphism (RFLP) of the tumor necrosis factor (TNFα) region in primary biliary cirrhosis and in healthy Danes. Scand. J Immunol 1989; 30: 185.
43. Shimura T, Hagihara M, Takebe K, Munkhbat B, et al. 10.5 kb homozygote of tumor necrosis factor beta gene is associated with a better prognosis in gastric cancer patients. Cancer 1995; 75: 1450.
44. Tilg H, Trehu E, Shapiro L, et al. Induction of circulating soluble tumor necrosis factor receptor and interleukin 1 receptor antagonist following interleukin 1 alpha infusion in humans. Cytokine 1994; 6: 215.
45. Mitchell PJ, Tjian R. Transcriptional regulation in mammalian cells by sequence specific DNA binding proteins. Science 1989; 245: 371.
46. Turner DM, Grant SCD, Yonan N, et al. Cytokine genotypes and heart transplant rejection. Transplantation 1997; 64: 776.
47. Sankaran D, Turner DM, Johnson RW, et al. Interleukin-10 and tumor necrosis factor alpha gene polymorphisms predict renal transplant outcome. Eur J Immunogenet 1997; 24: 65.
48. Asderakis A, Pravica V, Dyer PA, Sinnot PJ, Hutchinson IV. CA repeat polymorphism in the first intron of the interferon-γ (INF-γ) gene. Immunology 1997; 92 (suppl 1): 15.8.